Circassia Group PLC
LSE:CIR

Watchlist Manager
Circassia Group PLC Logo
Circassia Group PLC
LSE:CIR
Watchlist
Price: 36.5 GBX 0.83%
Market Cap: 152.7m GBX

Circassia Group PLC
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Circassia Group PLC
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Circassia Group PLC
LSE:CIR
Net Income (Common)
ÂŁ16.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Net Income (Common)
-$235.8m
CAGR 3-Years
15%
CAGR 5-Years
-116%
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Net Income (Common)
-$224.8m
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Net Income (Common)
-ÂŁ51.1m
CAGR 3-Years
27%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Net Income (Common)
ÂŁ19.3m
CAGR 3-Years
-22%
CAGR 5-Years
-11%
CAGR 10-Years
-7%
Oxford BioMedica PLC
LSE:OXB
Net Income (Common)
-ÂŁ37.1m
CAGR 3-Years
-15%
CAGR 5-Years
-24%
CAGR 10-Years
-14%
No Stocks Found

Circassia Group PLC
Glance View

Market Cap
153.1m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The firm operates through two segments: NIOX and COPD. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). The COPD segment relates to the Tudorza and Duaklir Pressair products marketed in the United States, where they are indicated for the maintenance treatment of patients with COPD. Its NIOX FeNO measurement and monitoring products are used by physicians around the world to help improve asthma diagnosis and management. Its FeNO diagnosis and management products helps healthcare to professionals manage their patient's asthma. Its NIOX VERO is a non-invasive, point-of-care system that provides FeNO measurements. The firm provides products and services in around 50 countries.

CIR Intrinsic Value
Not Available

See Also

What is Circassia Group PLC's Net Income (Common)?
Net Income (Common)
16.1m GBP

Based on the financial report for Dec 31, 2022, Circassia Group PLC's Net Income (Common) amounts to 16.1m GBP.

What is Circassia Group PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
347%

Over the last year, the Net Income (Common) growth was 347%.

Back to Top